Protagenic Therapeutics Dirección

Dirección controles de criterios 1/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	no data
Participación del CEO	n/a
Permanencia media de la dirección	sin datos
Promedio de permanencia en la Junta Directiva	5.8yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

Protagenic Therapeutics no tiene CEO, o no tenemos datos al respecto.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Garo Armen	Co-Founder & Executive Chairman of the Board	no data	sin datos	16.53% $ 449.0k
Robert Stein	Chief Medical Officer & Director	8.8yrs	sin datos	sin datos
Timothy Wright	Independent Director	2yrs	sin datos	sin datos
Brian Corvese	Independent Director	7.3yrs	US$118.75k	sin datos
Khalil Barrage	Independent Director	no data	US$243.75k	3.38% $ 91.7k
Jennifer Buell	Independent Director	4.3yrs	sin datos	sin datos

5.8yrs

Permanencia media

66yo

Promedio de edad

Junta con experiencia: La junta directiva de PTIX se considera experimentada (5.8 años de antigüedad promedio).

Protagenic Therapeutics Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

Protagenic Therapeutics, Inc., Annual General Meeting, Dec 13, 2023

Protagenic Therapeutics, Inc. Appoints Timothy R. Wright as a Class I Director

Protagenic Therapeutics, Inc., Annual General Meeting, Nov 23, 2022

Recent updates

Protagenic Therapeutics Receives A Delist Determination Letter from the Nasdaq

New major risk - Financial position

Protagenic Therapeutics, Inc. announced that it expects to receive $1.275 million in funding

Protagenic Therapeutics, Inc. Receives A Deficiency Letter from the Nasdaq Listing Qualifications Regarding Minimum Bid Price Requirement

New minor risk - Shareholder dilution

Protagenic Therapeutics Receives Deficiency Letter from Nasdaq Regarding Non-Compliance with the Minimum Stockholders’ Equity Requirement Set Forth in Nasdaq Listing Rule 5550(b)(1)

Protagenic Therapeutics, Inc. Completes Enrollment in Single Dose Portion of Phase 1 of Innovative Stress Disorder Trial

New major risk - Share price stability

New major risk - Financial position

Protagenic Therapeutics Successfully Concludes Third Cohort in Single Dose Portion of Phase 1 Trial for Stress-Related Neuropsychiatric Disorders

Protagenic Therapeutics, Inc. to Report Q4, 2023 Results on Apr 01, 2024

New major risk - Share price stability

Protagonist Therapeutics, Inc. Reports 2-Year Follow Up Data from Rusfertide REVIVE Study at the ASH Annual Meeting Showing Durable Efficacy and No New Safety Signals

Protagenic Therapeutics Receives Deficiency Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirements Set in Nasdaq Listing Rule 5550(a)(2) for Continued Listing on The Nasdaq Capital Market

New minor risk - Shareholder dilution

Protagenic Therapeutics, Inc., Annual General Meeting, Dec 13, 2023

New minor risk - Share price stability

Protagenic Therapeutics, Inc. Appoints Timothy R. Wright as a Class I Director

Protagenic Therapeutics, Inc., Annual General Meeting, Nov 23, 2022

Protagenic Therapeutics, Inc. announced delayed annual 10-K filing

Protagenic Therapeutics, Inc's Common Stock Deleted from Other OTC

Protagenic Therapeutics, Inc. has completed a Composite Units Offering in the amount of $13.197 million.

Protagenic Therapeutics, Inc. Announces Dr. Maurizio Fava of Massachusetts General Hospital to Serve as Principal Investigator for PT00114 Clinical Trial

Protagenic Therapeutics, Inc. announced that it has received $2 million in funding

Protagenic Therapeutics, Inc. announced that it has received $0.4275 million in funding

Protagenic Therapeutics, Inc. announced that it expects to receive $0.475 million in funding

CEO

Miembros de la Junta

Permanencia media

Promedio de edad